News & Updates

A red magnifying glass.

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

Cyclophosphamide (CYC) and rituximab (RTX) show comparable therapeutic effects on ear, nose, and throat (ENT) symptoms in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

Novel device delivers improvements for BPH symptoms

Novel device delivers improvements for BPH symptoms

The Optilume™ BPH Catheter System, a novel minimally invasive surgical therapy (MIST), provided rapid improvements for men with benign prostatic hyperplasia (BPH), the PINNACLE trial reports.

Novel device delivers improvements for BPH symptoms

31 Mar 2023

Antibiotics linked to higher EAC risk

Antibiotics linked to higher EAC risk

Exposure to any antibiotics appears to contribute to an increase in the risk of esophageal adenocarcinoma (EAC), with the risk rising as the cumulative days of exposure increases, according to a study.

Antibiotics linked to higher EAC risk

Original New Drug Application Approvals by US FDA (16-31 March 2023)

Original New Drug Application Approvals by US FDA (16-31 March 2023)

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2023)

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

Treatment with tenofovir disoproxil fumarate (TDF) yields similar rates of recurrence and overall survival as does entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study.

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

Chemo-induced nausea? Putting on some music may help, study suggests

Chemo-induced nausea? Putting on some music may help, study suggests

For people undergoing chemotherapy, tuning in to some music may help soothe nausea symptoms, as reported in a small pilot study.

Chemo-induced nausea? Putting on some music may help, study suggests

30 Mar 2023

Young adults with SLE at higher risk of 30-day rehospitalization

Young adults with SLE at higher risk of 30-day rehospitalization

A Medicare cohort study has found a very high 30-day rehospitalization rate among young adults with systemic lupus erythematosus (SLE).

Young adults with SLE at higher risk of 30-day rehospitalization

30 Mar 2023

Ceftolozane/tazobactam safe, effective in complicated UTI

Ceftolozane/tazobactam safe, effective in complicated UTI

Combination therapy with ceftolozane and tazobactam demonstrates a favourable safety profile in children with complicated urinary tract infection (cUTI) similar to that of meropenem and to the previously reported safety profile in adults with cUTI, a study has shown.

Ceftolozane/tazobactam safe, effective in complicated UTI

30 Mar 2023

Sweetened drink fructose tied to harmful levels of cardiometabolic biomarkers

Sweetened drink fructose tied to harmful levels of cardiometabolic biomarkers

Consumption of fructose from sweetened beverages contributes to unfavourable profiles of several cardiometabolic biomarkers, reveals a study.

Sweetened drink fructose tied to harmful levels of cardiometabolic biomarkers

Remdesivir cuts mortality in COVID-19 patients requiring no or low-flow oxygen

Remdesivir cuts mortality in COVID-19 patients requiring no or low-flow oxygen

In a systematic review and individual patient data meta-analysis, the broad-spectrum antiviral agent remdesivir reduced mortality in adult patients hospitalized for COVID-19 who did not require oxygen support or only required low-flow supplementation when the need for oxygen arose.

Remdesivir cuts mortality in COVID-19 patients requiring no or low-flow oxygen

30 Mar 2023

Something went wrong.